Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Heart Disease: Page 2
Physician, medical office to pay more than $2.6M involving clinical lab kickbacks
By
LabPulse.com staff writers
Feel Well Health and its owner violated the Anti-Kickback Statute by receiving remuneration from Boston Heart Diagnostics for clinical laboratory services for Medicare patients, according to the DOJ.
November 15, 2022
UK Biobank study links COVID-19 infection with poor cardiovascular health
By
Jared Berberabe
Individuals who have been hospitalized because of COVID-19 infection have a higher risk of experiencing adverse cardiovascular health outcomes, according to a UK Biobank study.
October 27, 2022
QuidelOrtho to invest 750K in heart disease awareness
By
LabPulse.com staff writers
As part of the collaboration, Quidel will invest the funding and give support for campaigns and initiatives led by the AHA's San Diego division.
June 21, 2022
Study to use genetic testing to evaluate heart disease
By
LabPulse.com staff writers
Researchers from Dignity Health's Chandler Regional Medical Center, Mercy Gilbert Medical Center, and St. Joseph's Hospital and Medical Center will gather approximately 2,000 DNA samples from men and women between the ages of 40 and 60 with no known history of heart disease. The samples will be analyzed for genetic markers known to cause heart disease at Baylor College of Medicine's Human Genome Sequencing Center Clinical Lab in Houston.
February 22, 2022
Cardio Diagnostics debuts coronary heart disease test
By
LabPulse.com staff writers
Primary care clinicians currently use two tools -- the Framingham Risk Score (FRS) and the Atherosclerotic Cardiovascular Disease (ASCVD) Risk Calculator -- for predicting future heart disease but both have low sensitivity, according to Cardio Diagnostics.
January 28, 2021
Fujifilm Medical to add IVD to portfolio
By
LabPulse.com staff writers
Fujifilm Wako Diagnostics has developed biomarkers that assess the risk of hepatocellular carcinoma in patients with chronic liver disease, as well as IVD reagents for disorders of lipid metabolism, lupus, rheumatoid arthritis, coronary heart disease, and diabetes, according to Fujifilm Medical Systems.
August 16, 2020
Heart association offers advice on who should get genetic testing
By
Theresa Pablos
Published on July 13 in Circulation: Genomic and Precision Medicine, the statement provides information on what the scientific community does and doesn't know about genes and genetic combinations that may influence heritable heart disease risk.
July 23, 2020
Week in Review: Coronavirus stool samples under scrutiny | Testing company accused of fraud | Genetic risk scoring in heart disease
By
Emily Hayes
Dear LabPulse Member,
June 11, 2020
Who stands to gain from polygenic risk scoring for heart disease?
By
Emily Hayes
The retrospective study evaluated the value of polygenic risk scores (PRSs) in a total of 47,108 middle-aged people (mean, 60 years) treated at hospitals affiliated with three different U.S. institutions on the East Coast: Partners HealthCare (MA), the University of Pennsylvania Health System (PA), and the Mount Sinai Health System (NY).
June 9, 2020
American College of Cardiology paves way for return of diagnostics
By
LabPulse.com staff writers
The pandemic has restricted routine medical care, including invasive procedures to treat heart disease and diagnostic tests to diagnose it, the ACC said. Delays in this care can increase patients' risk of adverse outcomes, according to the college.
May 4, 2020
Could a 5th 'vital sign' curb the spread of COVID-19?
By
Kate Madden Yee
A typical patient evaluation includes an assessment of temperature, heart rate, respiratory rate, and blood pressure. But in the context of COVID-19, adding travel history is key, wrote a research pair led by Dr. Trish Perl, chief of the division of infectious diseases at the University of Texas Southwestern Medical Center.
March 2, 2020
Genetic risk scoring not ready for prime time in heart disease
By
Emily Hayes
One study evaluated risk scoring in a cohort of participants in UK Biobank, a nonprofit research project that is performing whole genome sequencing on a mass scale in the U.K. The observational study assessed polygenic risk scores, pooled cohort equations (risk prediction models), and both combined for predicting events in 352,660 participants with no cardiovascular disease at baseline.
February 18, 2020
Previous Page
Page 2 of 3
Next Page